NO307283B1 - Anvendelse av et androgent steroid for aktivering av androgenreseptorer, partikler med vedvarende frigivningseffekt inneholdende slikt steroid, preparat inneholdende partiklene, og fremgangsmåte for fjerning av resterende organisk opploesningsmid - Google Patents

Anvendelse av et androgent steroid for aktivering av androgenreseptorer, partikler med vedvarende frigivningseffekt inneholdende slikt steroid, preparat inneholdende partiklene, og fremgangsmåte for fjerning av resterende organisk opploesningsmid

Info

Publication number
NO307283B1
NO307283B1 NO934742A NO934742A NO307283B1 NO 307283 B1 NO307283 B1 NO 307283B1 NO 934742 A NO934742 A NO 934742A NO 934742 A NO934742 A NO 934742A NO 307283 B1 NO307283 B1 NO 307283B1
Authority
NO
Norway
Prior art keywords
steroid
sustained release
particles
organic solvent
methods
Prior art date
Application number
NO934742A
Other languages
English (en)
Norwegian (no)
Other versions
NO934742D0 (no
NO934742L (no
Inventor
Fernand Labrie
Martin Lepage
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Publication of NO934742D0 publication Critical patent/NO934742D0/no
Publication of NO934742L publication Critical patent/NO934742L/no
Publication of NO307283B1 publication Critical patent/NO307283B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
NO934742A 1991-06-28 1993-12-21 Anvendelse av et androgent steroid for aktivering av androgenreseptorer, partikler med vedvarende frigivningseffekt inneholdende slikt steroid, preparat inneholdende partiklene, og fremgangsmåte for fjerning av resterende organisk opploesningsmid NO307283B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72453291A 1991-06-28 1991-06-28
US07/900,817 US5434146A (en) 1991-06-28 1992-06-24 Controlled release systems and low dose androgens
PCT/CA1992/000275 WO1993000070A1 (en) 1991-06-28 1992-06-26 Controlled release systems and low dose androgens

Publications (3)

Publication Number Publication Date
NO934742D0 NO934742D0 (no) 1993-12-21
NO934742L NO934742L (no) 1993-12-21
NO307283B1 true NO307283B1 (no) 2000-03-13

Family

ID=27110991

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934742A NO307283B1 (no) 1991-06-28 1993-12-21 Anvendelse av et androgent steroid for aktivering av androgenreseptorer, partikler med vedvarende frigivningseffekt inneholdende slikt steroid, preparat inneholdende partiklene, og fremgangsmåte for fjerning av resterende organisk opploesningsmid

Country Status (18)

Country Link
US (5) US5434146A (hu)
EP (1) EP0591311B1 (hu)
JP (1) JPH06508624A (hu)
AT (1) ATE161173T1 (hu)
AU (2) AU672750B2 (hu)
CA (1) CA2112393A1 (hu)
CZ (1) CZ285972B6 (hu)
DE (1) DE69223620T2 (hu)
FI (1) FI935893A0 (hu)
HU (1) HU222501B1 (hu)
IE (1) IE922123A1 (hu)
IL (3) IL102447A (hu)
MY (1) MY131099A (hu)
NO (1) NO307283B1 (hu)
NZ (4) NZ314568A (hu)
RU (1) RU2142276C1 (hu)
SK (1) SK280697B6 (hu)
WO (1) WO1993000070A1 (hu)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US20020091155A1 (en) * 1995-06-22 2002-07-11 Btg Pharmaceutical Corp. Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
AU5855794A (en) * 1993-01-19 1994-08-15 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5574011A (en) * 1995-04-04 1996-11-12 Tien; Henry C. Compositions and methods for the treatment of male-pattern baldness
US5910492A (en) * 1995-06-05 1999-06-08 Takeda Chemical Industries, Ltd. Osteogenic promoting pharmaceutical composition
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6576659B1 (en) * 1996-12-05 2003-06-10 Bio-Technology General Corp. Use of oxandrolone in the treatment of burns an other wounds
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US6028057A (en) * 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
BR9908592A (pt) * 1998-03-11 2001-04-24 Endorech Inc Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
KR100293504B1 (ko) 1998-06-05 2001-07-12 김윤 서방형전립선염치료제조성물
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
AU4957999A (en) * 1998-07-17 2000-02-07 Pharmacia & Upjohn Company Subcutaneous medroxyprogesterone acetate for contraception
JP2002527380A (ja) * 1998-10-09 2002-08-27 ファルマシア・アンド・アップジョン・カンパニー 閉経および子宮内膜症の治療用の皮下酢酸メドロキシプロゲステロン
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6613758B1 (en) 1999-04-02 2003-09-02 Barr Laboratories, Inc. Method for treating osteoporosis in castrated prostatic cancer patients
WO2000062759A1 (en) * 1999-04-16 2000-10-26 Novo Nordisk A/S Dry, mouldable drug formulation
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
US6187750B1 (en) 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
US6846496B1 (en) 1999-10-15 2005-01-25 Orion Corporation Treatment of osteoporosis
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6705757B2 (en) * 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6682754B2 (en) * 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
AP2002002552A0 (en) 1999-12-23 2002-06-30 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations.
US6562790B2 (en) 2000-02-05 2003-05-13 Chein Edmund Y M Hormone therapy methods and hormone products for abating coronary artery blockage
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US7018645B1 (en) * 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
FR2811218B1 (fr) 2000-07-05 2003-02-28 Patrice Suslian Dispositif implantable destine a corriger l'incontinence urinaire
DE60127139T2 (de) * 2000-07-14 2007-12-13 Novo Nordisk A/S Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
CA2453050A1 (en) * 2000-09-06 2002-03-14 A.P. Pharma, Inc. Degradable polyacetal polymers
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) * 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US20060205995A1 (en) * 2000-10-12 2006-09-14 Gyne Ideas Limited Apparatus and method for treating female urinary incontinence
GB0025068D0 (en) * 2000-10-12 2000-11-29 Browning Healthcare Ltd Apparatus and method for treating female urinary incontinence
US8167785B2 (en) 2000-10-12 2012-05-01 Coloplast A/S Urethral support system
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20020114843A1 (en) * 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
GB0108088D0 (en) * 2001-03-30 2001-05-23 Browning Healthcare Ltd Surgical implant
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
AU2002366800B2 (en) 2001-12-20 2006-08-03 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
JP2005519964A (ja) * 2002-03-11 2005-07-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファターゼ阻害プロゲストゲンのみの避妊レジメン
EP1492459A2 (en) * 2002-04-11 2005-01-05 Gyne Ideas Limited Apparatus and method for treating female urinary incontinence
EP1829529A1 (en) * 2002-05-03 2007-09-05 PR Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
EP1507514B1 (en) * 2002-05-03 2007-02-14 PR Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
DE60334919D1 (de) 2002-08-02 2010-12-23 Bard Inc C R Selbstverankerndes schlingen- und einführsystem
MXPA05007266A (es) * 2003-01-02 2006-01-17 Femmepharma Holding Co Inc Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
GB0307082D0 (en) 2003-03-27 2003-04-30 Gyne Ideas Ltd Drug delivery device and method
US6992075B2 (en) 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
MXPA05010871A (es) * 2003-04-11 2005-11-25 Barr Lab Inc Metodos para administrar estrogenos y progestinas.
US7056591B1 (en) 2003-07-30 2006-06-06 Advanced Cardiovascular Systems, Inc. Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same
JP5651279B2 (ja) 2003-09-03 2015-01-07 ミスコン トレイディング エス．エー． 子宮内膜症の処置のための方法
ES2555681T3 (es) * 2003-10-03 2016-01-07 Thorn Bioscience, Llc Procedimiento para la sincronización de la ovulación para la fecundación programada sin detección del celo
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US7220816B2 (en) * 2003-12-16 2007-05-22 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US7435788B2 (en) * 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
WO2005068020A1 (en) * 2004-01-02 2005-07-28 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
US8685431B2 (en) * 2004-03-16 2014-04-01 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
WO2005110425A1 (en) 2004-04-15 2005-11-24 Alkermes, Inc. Polymer-based sustained release device
US7334330B2 (en) * 2004-04-28 2008-02-26 Siemens Power Generation, Inc. Thermally insulating layer incorporating a distinguishing agent and method for inspecting the same
US20050288481A1 (en) * 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
US7820732B2 (en) * 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
GB0411360D0 (en) 2004-05-21 2004-06-23 Mpathy Medical Devices Ltd Implant
US20050271700A1 (en) * 2004-06-03 2005-12-08 Desnoyer Jessica R Poly(ester amide) coating composition for implantable devices
US20050287184A1 (en) * 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
US7311980B1 (en) 2004-08-02 2007-12-25 Advanced Cardiovascular Systems, Inc. Polyactive/polylactic acid coatings for an implantable device
PT1781264E (pt) 2004-08-04 2013-10-16 Evonik Corp Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
US7166680B2 (en) * 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US8603634B2 (en) 2004-10-27 2013-12-10 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US20060089485A1 (en) * 2004-10-27 2006-04-27 Desnoyer Jessica R End-capped poly(ester amide) copolymers
US7390497B2 (en) * 2004-10-29 2008-06-24 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US8609123B2 (en) * 2004-11-29 2013-12-17 Advanced Cardiovascular Systems, Inc. Derivatized poly(ester amide) as a biobeneficial coating
US7419504B2 (en) * 2004-12-27 2008-09-02 Advanced Cardiovascular Systems, Inc. Poly(ester amide) block copolymers
US8007775B2 (en) * 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
US7202325B2 (en) 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
CA2601773A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1848410A4 (en) * 2005-02-17 2011-11-09 Medivas Llc COMPOSITIONS FOR DISPENSING POLYMER PARTICLES AND APPLICATION METHOD THEREFOR
US20070020312A1 (en) * 2005-07-20 2007-01-25 Desnoyer Jessica R Method of fabricating a bioactive agent-releasing implantable medical device
US8377462B2 (en) * 2005-07-29 2013-02-19 Advanced Cardiovascular Systems, Inc. PEA-TEMPO/PEA-BZ coatings for controlled delivery of drug from implantable medical devices
CA2623239C (en) * 2005-09-22 2016-07-12 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
US8445007B2 (en) 2005-09-22 2013-05-21 Medivas, Llc Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use
US20070077269A1 (en) * 2005-10-04 2007-04-05 Woodward John R Method of birth control and hormone regulation
JP5449775B2 (ja) 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
EP1962894A4 (en) * 2005-12-07 2012-11-14 Medivas Llc PROCESS FOR ASSEMBLING A BIOLOGICAL POLYMER-AGENT DELIVERY COMPOSITION
US20070135909A1 (en) * 2005-12-08 2007-06-14 Desnoyer Jessica R Adhesion polymers to improve stent retention
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
US7910152B2 (en) * 2006-02-28 2011-03-22 Advanced Cardiovascular Systems, Inc. Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
WO2007130477A2 (en) * 2006-05-02 2007-11-15 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
WO2007133616A2 (en) * 2006-05-09 2007-11-22 Medivas, Llc Biodegradable water soluble polymers
US8323676B2 (en) * 2008-06-30 2012-12-04 Abbott Cardiovascular Systems Inc. Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
US20090258028A1 (en) * 2006-06-05 2009-10-15 Abbott Cardiovascular Systems Inc. Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
US7771739B2 (en) * 2006-06-30 2010-08-10 Abbott Cardiovascular Systems Inc. Implantable medical devices comprising semi-crystalline poly(ester-amide)
US9028859B2 (en) * 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US8030436B2 (en) * 2006-07-13 2011-10-04 Advanced Cardiovascular Systems, Inc. Poly(ester-amide) elastomers and their use with implantable medical devices
US20090181063A1 (en) * 2006-07-13 2009-07-16 Michael Huy Ngo Implantable medical device comprising a pro-healing poly(ester-amide)
US7731987B2 (en) * 2006-07-13 2010-06-08 Advanced Cardiovascular Systems, Inc. Implantable medical device comprising a pro-healing poly(ester-amide)
US20080014245A1 (en) * 2006-07-14 2008-01-17 Stephen Pacetti Drug-eluting implantable medical device with free radical scavenger for protecting drugs during sterilization and related method
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2104489A2 (en) * 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
US20080175882A1 (en) * 2007-01-23 2008-07-24 Trollsas Mikael O Polymers of aliphatic thioester
EP2131815A4 (en) * 2007-03-22 2012-11-07 Alkermes Inc coacervation
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
US8252361B2 (en) * 2007-06-05 2012-08-28 Abbott Cardiovascular Systems Inc. Implantable medical devices for local and regional treatment
US20080306584A1 (en) * 2007-06-05 2008-12-11 Pamela Kramer-Brown Implantable medical devices for local and regional treatment
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
US9737638B2 (en) 2007-06-20 2017-08-22 Abbott Cardiovascular Systems, Inc. Polyester amide copolymers having free carboxylic acid pendant groups
US7927621B2 (en) * 2007-06-25 2011-04-19 Abbott Cardiovascular Systems Inc. Thioester-ester-amide copolymers
WO2009015143A1 (en) * 2007-07-24 2009-01-29 Medivas, Llc Biodegradable cationic polymer gene transfer compositions and methods of use
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
JP5502751B2 (ja) 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US8889172B1 (en) 2008-04-30 2014-11-18 Abbott Cardiovascular Systems Inc. Amorphous or semi-crystalline poly(ester amide) polymer with a high glass transition temperature
US8765162B2 (en) * 2008-06-30 2014-07-01 Abbott Cardiovascular Systems Inc. Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
EP2323671A4 (en) * 2008-08-13 2012-09-26 Medivas Llc BIODEGRADABLE AABB POLY (DEPSIPEPTIDE) POLYMERS AND METHOD FOR THEIR USE
US20100047319A1 (en) * 2008-08-21 2010-02-25 Michael Huy Ngo Biodegradable Poly(Ester-Amide) And Poly(Amide) Coatings For Implantable Medical Devices With Enhanced Bioabsorption Times
EP2398461A1 (en) 2009-02-18 2011-12-28 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US20120114757A1 (en) 2009-02-18 2012-05-10 Bayer Pharma Aktiengesellschaft Particles comprising drospirenone encapsulated in a polymer
DK2421545T3 (en) 2009-04-23 2018-03-12 Jbs United Animal Health Ii Llc PROCEDURE AND COMPOSITION TO SYNCHRONIZE THE TIME OF INSEMINATION.
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
CN103619910B (zh) 2011-06-23 2016-08-31 帝斯曼知识产权资产管理有限公司 用于药物递送的新颖的聚酯酰胺共聚物
MX353280B (es) * 2012-06-27 2018-01-05 Medincell Suministro de farmaco biodegradable para las composiciones hidrofobicas.
CN104994865A (zh) 2012-11-28 2015-10-21 杰碧斯联合动物健康第二有限责任公司 用于同步小母猪的授精时间的方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2965372C (en) 2014-10-22 2023-09-05 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
WO2016097297A1 (en) 2014-12-18 2016-06-23 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3364978A4 (en) 2015-10-22 2019-06-05 Havah Therapeutics Pty Ltd METHOD FOR REDUCING MAMMOGRAPHIC BREAST DENSITY AND / OR BREAST CANCER RISK
CA3004849A1 (en) 2015-11-16 2017-05-26 Georges Gaudriault A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
US11524014B2 (en) 2019-06-03 2022-12-13 Havah Therapeutics Pty Ltd. Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
CA1076480A (en) * 1975-04-28 1980-04-29 John S. Kent Inert core implant pellet
US4071622A (en) * 1976-02-11 1978-01-31 Abbott Laboratories Treatment of a mammary or DMBA inducible tumor
US4107071A (en) * 1977-02-16 1978-08-15 Capsulated Systems, Inc. Method of producing microcapsules and resulting product
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4522831A (en) * 1983-05-02 1985-06-11 Northwestern University Method of totally suppressing ovarian follicular development
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4736849A (en) * 1983-12-19 1988-04-12 Leonard Walter G Calendar-oriented pill dispenser
GB8403360D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
JPH0680016B2 (ja) * 1984-08-02 1994-10-12 ラブリ−，フエルナンド ホルモン依存性がんの併用治療のための医薬組成物
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
WO1986001110A1 (en) * 1984-08-08 1986-02-27 Survival Technology, Inc. Absorption enhancing agents
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
EP0357644B1 (en) * 1987-04-06 1994-08-17 Aberlyn Capital Management Limited Partnership Flash flow fused medicinal implants
AU2810189A (en) * 1987-10-30 1989-05-23 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US5023080A (en) * 1988-06-17 1991-06-11 Basic Bio Systems, Inc. Time release protein
JP2959838B2 (ja) * 1989-03-10 1999-10-06 アンドルシェルシュ・インコーポレイテッド エストロゲン感受性疾患の治療のための組合せ療法
DE3908792A1 (de) * 1989-03-17 1990-09-20 Huels Chemische Werke Ag Verfahren zur herstellung unsymmetrischer, endstaendig einfach ungesaettigter glykolether
US5043331A (en) * 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens

Also Published As

Publication number Publication date
IE922123A1 (en) 1992-12-30
AU2182092A (en) 1993-01-25
EP0591311B1 (en) 1997-12-17
FI935893A (fi) 1993-12-28
US5861387A (en) 1999-01-19
NZ314568A (en) 2000-09-29
IL102402A0 (en) 1993-01-14
JPH06508624A (ja) 1994-09-29
SK280697B6 (sk) 2000-06-12
HU222501B1 (hu) 2003-07-28
WO1993000070A1 (en) 1993-01-07
NZ264279A (en) 1996-05-28
US5541172A (en) 1996-07-30
AU6587996A (en) 1996-12-19
NZ272633A (en) 1997-06-24
CZ285972B6 (cs) 1999-12-15
ATE161173T1 (de) 1998-01-15
NZ243370A (en) 1996-02-27
HU9303716D0 (en) 1994-04-28
AU707401B2 (en) 1999-07-08
AU672750B2 (en) 1996-10-17
NO934742D0 (no) 1993-12-21
DE69223620D1 (de) 1998-01-29
FI935893A0 (fi) 1993-12-28
US5814340A (en) 1998-09-29
SK147893A3 (en) 1994-09-07
CZ290893A3 (en) 1994-10-19
DE69223620T2 (de) 1998-04-23
IL102447A0 (en) 1993-01-14
CA2112393A1 (en) 1993-01-07
IL120025A0 (en) 1997-04-15
NO934742L (no) 1993-12-21
MY131099A (en) 2007-07-31
US5434146A (en) 1995-07-18
HUT66859A (en) 1995-01-30
US5629303A (en) 1997-05-13
EP0591311A1 (en) 1994-04-13
RU2142276C1 (ru) 1999-12-10
IL102447A (en) 1998-03-10

Similar Documents

Publication Publication Date Title
NO307283B1 (no) Anvendelse av et androgent steroid for aktivering av androgenreseptorer, partikler med vedvarende frigivningseffekt inneholdende slikt steroid, preparat inneholdende partiklene, og fremgangsmåte for fjerning av resterende organisk opploesningsmid
TW363892B (en) Pharmaceutical compositions for treating or preventing breast cancer, endometrial cancer, osteoporosis or endometriosis or for contraception and sustained release particles containing therein
RU93058524A (ru) Системы с регулируемым высвобождением и низкими дозами андрогенов, способ их получения и способ лечения с помощью этих систем
Swerdloff et al. Control of LH and FSH secretion in the male: evidence that aromatization of androgens to estradiol is not required for inhibition of gonadotropin secretion
Chart et al. New amphenone analogs as adrenocortical inhibitors
Conney et al. Induction of liver microsomal cortisol 6β-hydroxylase by diphenylhydantoin or phenobarbital: An explanation for the increased excretion of 6-hydroxycortisol in humans treated with these drugs
Gay et al. Serum LH and FSH following passive immunization against circulating testosterone in the intact male rat and in orchidectomized rats bearing subcutaneous silastic implants of testosterone
AU692411B2 (en) Androgen derivatives for use in the inhibition of sex steroid activity
Janssens et al. The effect of chronic stress on plasma cortisol concentrations in cyclic female pigs depends on the time of day
AU5513194A (en) Combination therapy for treatment of estrogen sensitive diseases
NO981315L (no) Transdermalt matrikssystem
Nolin et al. Does androgen influence prolactin secretion?
D'occhio et al. Effects of androgenic and oestrogenic hormones on mating behaviour in rams castrated before or after puberty
ATE255898T1 (de) Androstansteroide als neurochemische initiatoren einer veränderung der hypothalamusfunktion beim menschen und verwandte pharmazeutische präparate und verfahren
LIAS et al. A detailed in vitro characterization of the basal follicle-stimulating hormone and luteinizing hormone secretion rates during the rat four-day estrous cycle
MXPA05010871A (es) Metodos para administrar estrogenos y progestinas.
Steinetz et al. The role of growth hormone in the anabolic action of methandrostenolone
Segal Male fertility control studies: An editorial comment
Bieglmayer et al. Nuclear translocation of the rat pituitary cytosol 17β-estradiol receptor
Lamberts et al. Effects of megestrol acetate on growth and secretion of a pituitary tumor
DE59900775D1 (de) Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate
Göretzlehner et al. The modulating effect of estrogens on luteinizing hormone release in complete androgen insensitivity syndrome before and after gonadectomy and cyclic steroid application
Chowdhury et al. Effects of oestradiol benzoate (OeB) and human chorionic gonadotrophin (hCG) on the testes and accessory sex glands of the rat
Diassi et al. Steroid Hormones and their Antagonists
EA007601B1 (ru) СОДЕРЖАЩАЯ ОБЛАДАЮЩИЙ АНДРОГЕННЫМ ДЕЙСТВИЕМ 11β-ГАЛОГЕНСТЕРОИД И ГЕСТАГЕН КОМПОЗИЦИЯ И МУЖСКОЙ КОНТРАЦЕПТИВ НА ОСНОВЕ ЭТОЙ КОМПОЗИЦИИ